Papers
9
Total Citations
441
H-Index
8
About
Dr. Ravi Rajaram is a leading thoracic surgeon whose research centers on optimizing surgical outcomes for non-small cell lung cancer (NSCLC) through minimally invasive techniques and novel immunotherapy combinations. His landmark work includes a nationwide assessment of robotic lobectomy, demonstrating its safety and efficacy with over 100 citations, and a comprehensive institutional experience further validating robotic-assisted approaches. Dr. Rajaram has been at the forefront of integrating immunotherapy into surgical care, notably studying surgical outcomes after neoadjuvant nivolumab with or without ipilimumab—a highly cited 2022 study (94 citations) that helped shape perioperative treatment paradigms. His research also addresses critical postoperative challenges, including opioid use patterns after lung resection, with studies analyzing both Premier hospital data and Medicare populations. Beyond technique and recovery, Dr. Rajaram has contributed to defining benchmarks for recurrence-free survival in surgically resected NSCLC, providing essential evidence for prognosis and follow-up. With over 400 total citations across his most influential works, his research bridges robotic innovation, immunotherapy integration, and patient-centered outcomes, making him a key voice in modern thoracic oncology.
Research Focus
Key Achievements
Top Papers
- 1Nationwide Assessment of Robotic Lobectomy for Non-Small Cell Lung Cancer107 citations · 2017
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9Robotic surgical techniques for standard segmentectomies2 citations · 2020